Home › Research › Inflammation and the immune system
Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions
João Vitor Mello-Hortega, Carolina Souza-de Oliveira, Vitória Emily Santana De Araújo, Lupe Furtado Alle, Luciane Viater Tureck, Ricardo Lehtonen Rodrigues de Souza. European Journal of Neuroscience, 2025-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a set of multifactorial conditions that progressively impair memory processing and cognitive function. The study of this pathology is particularly challenging due to its complex etiology, which involves several pathological hallmarks, including amyloid plaque formation, tau protein hyperphosphorylation, neuroinflammation, oxidative stress, and other contributing factors-all leading to neuronal loss. The primary therapeutic approach for AD involves the use of anticholinesterase agents; however, these treatments are associated with adverse effects, and their efficacy has been increasingly questioned. Against this backdrop, researchers have investigated cannabidiol (CBD) as a potential complementary treatment for AD. This study compiles and synthesizes current evidence regarding the therapeutic effects of CBD in the context of AD, examining its impact on the amyloid cascade, tau phosphorylation, neuroinflammation, oxidative stress, the cholinergic pathway, glucose and lipid metabolism, behavioral alterations, and physiological changes. In addition, an in silico analysis was conducted based on studies that identified differential gene expression in response to CBD. Through this analysis, we mapped the gene network and biological pathways involved in CBD's mechanism of action in AD, contributing to the identification of potential gene targets for further research and providing deeper insight into its therapeutic potential.
What this study adds
Evidence grade: Low
This review summarizes evidence on cannabidiol in Alzheimer's disease and uses computer-based analysis of gene networks and pathways. It is not a clinical trial, so it does not show that cannabidiol treats or prevents Alzheimer's disease in people.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mello-Hortega, J. V., Oliveira, C. S.-d., De Araújo, V. E. S., Alle, L. F., Tureck, L. V., & de Souza, R. L. R. (2025). Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70229
Vancouver
Mello-Hortega JV, Oliveira CS.-d, De Araújo VES, Alle LF, Tureck LV, de Souza RLR. Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions. European Journal of Neuroscience. 2025. doi:10.1111/ejn.70229. PMID: 40859865.
BibTeX
@article{mellohortega2025-40859865,
author = {Mello-Hortega, João Vitor and Oliveira, Carolina Souza-de and De Araújo, Vitória Emily Santana and Alle, Lupe Furtado and Tureck, Luciane Viater and de Souza, Ricardo Lehtonen Rodrigues},
title = {{Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions}},
journal = {European Journal of Neuroscience},
year = {2025},
doi = {10.1111/ejn.70229},
pmid = {40859865},
url = {https://doi.org/10.1111/ejn.70229}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The primary therapeutic approach for AD involves the use of anticholinesterase agents; however, these treatments are associated with adverse effects, and their efficacy has been increasingly questioned.
Why it matters
This review summarizes evidence on cannabidiol in Alzheimer's disease and uses computer-based analysis of gene networks and pathways. It is not a clinical trial, so it does not show that cannabidiol treats or prevents Alzheimer's disease in people.
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Journal of Neuroscience) |
| Journal's citation record | 3 / 4 | European Journal of Neuroscience: journal h-index 277 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Ricardo Lehtonen Rodrigues de Souza: h-index 20 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidade Federal do Paraná: institution h-index 372 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40859865) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/ejn.70229
- PubMed: 40859865
- Original source →
- Free full text: European Journal of Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Inflammation and the immune system from nearby years
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.